Anna Testa, Fabio Quaglia, Nicole M Naranjo, Cecilia E Verrillo, Christopher D Shields, Stephen Lin, Maxwell W Pickles, Drini F Hamza, Tami Von Schalscha, David A Cheresh, Benjamin Leiby, Qin Liu, Jianyi Ding, William K Kelly, D Craig Hooper, Eva Corey, Edward F Plow, Dario C Altieri, Lucia R Languino
Highly aggressive, metastatic, neuroendocrine prostate cancer, which typically develops from prostate cancer cells acquiring resistance to androgen deprivation therapy, is associated with limited treatment options and hence poor prognosis. We have previously demonstrated that the αVβ3 integrin is over-expressed in neuroendocrine prostate cancer. We now show that LM609, a monoclonal antibody that specifically targets the human αVβ3 integrin, hinders the growth of neuroendocrine prostate cancer patient-derived xenografts in vivo...
November 11, 2023: Matrix Biology: Journal of the International Society for Matrix Biology